Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Research Report 2026(Status and Outlook)
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on First in Class (FIC) Antibody Drug Conjugate (ADC) competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.A First-in-Class Antibody-Drug Conjugate (FIC ADC) is an innovative targeted cancer therapy that combines a monoclonal antibody, a cytotoxic payload, and a linker, and is the first approved therapeutic to act on a novel target or molecular mechanism in its class. These ADCs represent the first therapeutic option to deliver a toxic agent specifically to a previously untargeted cell surface antigen or use a unique payload mechanism.
The global First in Class (FIC) Antibody Drug Conjugate (ADC) market size was estimated at USD 2315.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 12.30% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global First in Class (FIC) Antibody Drug Conjugate (ADC) market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global First in Class (FIC) Antibody Drug Conjugate (ADC) market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the First in Class (FIC) Antibody Drug Conjugate (ADC) market.
Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Pfizer
Johnson & Johnson
AstraZeneca
Arvinas
GSK
Bayer Corporation
Pumis Biotechnology (BioNTech)
Telix
Merus
Bicara Therapeutics
Immatics
Fabhalta
Lytgobi
Talvey
Regeneron Pharmaceuticals
Ogsiveo
Skyclary
Truqap
Litfulo
Vertex Pharmaceuticals
Jiangsu Hengrui Medicine
Akeso, Inc
Dizal Pharma
Shenzhen Yipusheng
Foreseen Biotechnology
Shanghai Henlius Biotech, Inc.
Suzhou Yilian Biopharmaceutical
Beijing Hotgen Biotech
Lixin Pharmaceutical Technology
Suzhou Zejing Biopharmaceutical
Market Segmentation (by Type)
Large Molecule FIC Drugs
Small Molecule FIC Drugs
Market Segmentation (by Application)
Tumors and Cancers
Others
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the First in Class (FIC) Antibody Drug Conjugate (ADC) Market
Overview of the regional outlook of the First in Class (FIC) Antibody Drug Conjugate (ADC) Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the First in Class (FIC) Antibody Drug Conjugate (ADC) Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of First in Class (FIC) Antibody Drug Conjugate (ADC), their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
The global First in Class (FIC) Antibody Drug Conjugate (ADC) market size was estimated at USD 2315.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 12.30% during the forecast period.
This report offers a comprehensive and in-depth analysis of the global First in Class (FIC) Antibody Drug Conjugate (ADC) market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.
The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.
A significant focus of this report lies in the competitive landscape of the global First in Class (FIC) Antibody Drug Conjugate (ADC) market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.
In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the First in Class (FIC) Antibody Drug Conjugate (ADC) market.
Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market: Market Segmentation Analysis
This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.
A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.
Key Company
Pfizer
Johnson & Johnson
AstraZeneca
Arvinas
GSK
Bayer Corporation
Pumis Biotechnology (BioNTech)
Telix
Merus
Bicara Therapeutics
Immatics
Fabhalta
Lytgobi
Talvey
Regeneron Pharmaceuticals
Ogsiveo
Skyclary
Truqap
Litfulo
Vertex Pharmaceuticals
Jiangsu Hengrui Medicine
Akeso, Inc
Dizal Pharma
Shenzhen Yipusheng
Foreseen Biotechnology
Shanghai Henlius Biotech, Inc.
Suzhou Yilian Biopharmaceutical
Beijing Hotgen Biotech
Lixin Pharmaceutical Technology
Suzhou Zejing Biopharmaceutical
Market Segmentation (by Type)
Large Molecule FIC Drugs
Small Molecule FIC Drugs
Market Segmentation (by Application)
Tumors and Cancers
Others
Geographic Segmentation
North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the First in Class (FIC) Antibody Drug Conjugate (ADC) Market
Overview of the regional outlook of the First in Class (FIC) Antibody Drug Conjugate (ADC) Market:
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the First in Class (FIC) Antibody Drug Conjugate (ADC) Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 shares the main producing countries of First in Class (FIC) Antibody Drug Conjugate (ADC), their output value, profit level, regional supply, production capacity layout, etc. from the supply side.
Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.
Chapter 13 is the main points and conclusions of the report.
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of First in Class (FIC) Antibody Drug Conjugate (ADC)
1.2 Key Market Segments
1.2.1 First in Class (FIC) Antibody Drug Conjugate (ADC) Segment by Type
1.2.2 First in Class (FIC) Antibody Drug Conjugate (ADC) Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 FIRST IN CLASS (FIC) ANTIBODY DRUG CONJUGATE (ADC) MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 FIRST IN CLASS (FIC) ANTIBODY DRUG CONJUGATE (ADC) MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Product Life Cycle
3.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Manufacturers (2020-2025)
3.4 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Manufacturers (2020-2025)
3.5 First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 First in Class (FIC) Antibody Drug Conjugate (ADC) Market Competitive Situation and Trends
3.8.1 First in Class (FIC) Antibody Drug Conjugate (ADC) Market Concentration Rate
3.8.2 Global 5 and 10 Largest First in Class (FIC) Antibody Drug Conjugate (ADC) Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 FIRST IN CLASS (FIC) ANTIBODY DRUG CONJUGATE (ADC) INDUSTRY CHAIN ANALYSIS
4.1 First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF FIRST IN CLASS (FIC) ANTIBODY DRUG CONJUGATE (ADC) MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to First in Class (FIC) Antibody Drug Conjugate (ADC) Market
5.7 ESG Ratings of Leading Companies
6 FIRST IN CLASS (FIC) ANTIBODY DRUG CONJUGATE (ADC) MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Type (2020-2025)
6.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Type (2020-2025)
6.4 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Price by Type (2020-2025)
7 FIRST IN CLASS (FIC) ANTIBODY DRUG CONJUGATE (ADC) MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Sales by Application (2020-2025)
7.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size (M USD) by Application (2020-2025)
7.4 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Growth Rate by Application (2020-2025)
8 FIRST IN CLASS (FIC) ANTIBODY DRUG CONJUGATE (ADC) MARKET SALES BY REGION
8.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region
8.1.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region
8.1.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Region
8.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region
8.2.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region
8.2.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region
8.3 North America
8.3.1 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country
8.3.2 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country
8.4.2 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region
8.5.2 Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country
8.6.2 South America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region
8.7.2 Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 FIRST IN CLASS (FIC) ANTIBODY DRUG CONJUGATE (ADC) MARKET PRODUCTION BY REGION
9.1 Global Production of First in Class (FIC) Antibody Drug Conjugate (ADC) by Region(2020-2025)
9.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Region (2020-2025)
9.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Production
9.4.1 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Production Growth Rate (2020-2025)
9.4.2 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Production
9.5.1 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Production Growth Rate (2020-2025)
9.5.2 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan First in Class (FIC) Antibody Drug Conjugate (ADC) Production (2020-2025)
9.6.1 Japan First in Class (FIC) Antibody Drug Conjugate (ADC) Production Growth Rate (2020-2025)
9.6.2 Japan First in Class (FIC) Antibody Drug Conjugate (ADC) Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China First in Class (FIC) Antibody Drug Conjugate (ADC) Production (2020-2025)
9.7.1 China First in Class (FIC) Antibody Drug Conjugate (ADC) Production Growth Rate (2020-2025)
9.7.2 China First in Class (FIC) Antibody Drug Conjugate (ADC) Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Pfizer
10.1.1 Pfizer Basic Information
10.1.2 Pfizer First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.1.3 Pfizer First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.1.4 Pfizer Business Overview
10.1.5 Pfizer SWOT Analysis
10.1.6 Pfizer Recent Developments
10.2 Johnson and Johnson
10.2.1 Johnson and Johnson Basic Information
10.2.2 Johnson and Johnson First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.2.3 Johnson and Johnson First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.2.4 Johnson and Johnson Business Overview
10.2.5 Johnson and Johnson SWOT Analysis
10.2.6 Johnson and Johnson Recent Developments
10.3 AstraZeneca
10.3.1 AstraZeneca Basic Information
10.3.2 AstraZeneca First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.3.3 AstraZeneca First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.3.4 AstraZeneca Business Overview
10.3.5 AstraZeneca SWOT Analysis
10.3.6 AstraZeneca Recent Developments
10.4 Arvinas
10.4.1 Arvinas Basic Information
10.4.2 Arvinas First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.4.3 Arvinas First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.4.4 Arvinas Business Overview
10.4.5 Arvinas Recent Developments
10.5 GSK
10.5.1 GSK Basic Information
10.5.2 GSK First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.5.3 GSK First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.5.4 GSK Business Overview
10.5.5 GSK Recent Developments
10.6 Bayer Corporation
10.6.1 Bayer Corporation Basic Information
10.6.2 Bayer Corporation First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.6.3 Bayer Corporation First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.6.4 Bayer Corporation Business Overview
10.6.5 Bayer Corporation Recent Developments
10.7 Pumis Biotechnology (BioNTech)
10.7.1 Pumis Biotechnology (BioNTech) Basic Information
10.7.2 Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.7.3 Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.7.4 Pumis Biotechnology (BioNTech) Business Overview
10.7.5 Pumis Biotechnology (BioNTech) Recent Developments
10.8 Telix
10.8.1 Telix Basic Information
10.8.2 Telix First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.8.3 Telix First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.8.4 Telix Business Overview
10.8.5 Telix Recent Developments
10.9 Merus
10.9.1 Merus Basic Information
10.9.2 Merus First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.9.3 Merus First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.9.4 Merus Business Overview
10.9.5 Merus Recent Developments
10.10 Bicara Therapeutics
10.10.1 Bicara Therapeutics Basic Information
10.10.2 Bicara Therapeutics First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.10.3 Bicara Therapeutics First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.10.4 Bicara Therapeutics Business Overview
10.10.5 Bicara Therapeutics Recent Developments
10.11 Immatics
10.11.1 Immatics Basic Information
10.11.2 Immatics First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.11.3 Immatics First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.11.4 Immatics Business Overview
10.11.5 Immatics Recent Developments
10.12 Fabhalta
10.12.1 Fabhalta Basic Information
10.12.2 Fabhalta First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.12.3 Fabhalta First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.12.4 Fabhalta Business Overview
10.12.5 Fabhalta Recent Developments
10.13 Lytgobi
10.13.1 Lytgobi Basic Information
10.13.2 Lytgobi First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.13.3 Lytgobi First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.13.4 Lytgobi Business Overview
10.13.5 Lytgobi Recent Developments
10.14 Talvey
10.14.1 Talvey Basic Information
10.14.2 Talvey First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.14.3 Talvey First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.14.4 Talvey Business Overview
10.14.5 Talvey Recent Developments
10.15 Regeneron Pharmaceuticals
10.15.1 Regeneron Pharmaceuticals Basic Information
10.15.2 Regeneron Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.15.3 Regeneron Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.15.4 Regeneron Pharmaceuticals Business Overview
10.15.5 Regeneron Pharmaceuticals Recent Developments
10.16 Ogsiveo
10.16.1 Ogsiveo Basic Information
10.16.2 Ogsiveo First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.16.3 Ogsiveo First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.16.4 Ogsiveo Business Overview
10.16.5 Ogsiveo Recent Developments
10.17 Skyclary
10.17.1 Skyclary Basic Information
10.17.2 Skyclary First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.17.3 Skyclary First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.17.4 Skyclary Business Overview
10.17.5 Skyclary Recent Developments
10.18 Truqap
10.18.1 Truqap Basic Information
10.18.2 Truqap First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.18.3 Truqap First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.18.4 Truqap Business Overview
10.18.5 Truqap Recent Developments
10.19 Litfulo
10.19.1 Litfulo Basic Information
10.19.2 Litfulo First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.19.3 Litfulo First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.19.4 Litfulo Business Overview
10.19.5 Litfulo Recent Developments
10.20 Vertex Pharmaceuticals
10.20.1 Vertex Pharmaceuticals Basic Information
10.20.2 Vertex Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.20.3 Vertex Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.20.4 Vertex Pharmaceuticals Business Overview
10.20.5 Vertex Pharmaceuticals Recent Developments
10.21 Jiangsu Hengrui Medicine
10.21.1 Jiangsu Hengrui Medicine Basic Information
10.21.2 Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.21.3 Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.21.4 Jiangsu Hengrui Medicine Business Overview
10.21.5 Jiangsu Hengrui Medicine Recent Developments
10.22 Akeso, Inc
10.22.1 Akeso, Inc Basic Information
10.22.2 Akeso, Inc First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.22.3 Akeso, Inc First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.22.4 Akeso, Inc Business Overview
10.22.5 Akeso, Inc Recent Developments
10.23 Dizal Pharma
10.23.1 Dizal Pharma Basic Information
10.23.2 Dizal Pharma First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.23.3 Dizal Pharma First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.23.4 Dizal Pharma Business Overview
10.23.5 Dizal Pharma Recent Developments
10.24 Shenzhen Yipusheng
10.24.1 Shenzhen Yipusheng Basic Information
10.24.2 Shenzhen Yipusheng First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.24.3 Shenzhen Yipusheng First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.24.4 Shenzhen Yipusheng Business Overview
10.24.5 Shenzhen Yipusheng Recent Developments
10.25 Foreseen Biotechnology
10.25.1 Foreseen Biotechnology Basic Information
10.25.2 Foreseen Biotechnology First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.25.3 Foreseen Biotechnology First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.25.4 Foreseen Biotechnology Business Overview
10.25.5 Foreseen Biotechnology Recent Developments
10.26 Shanghai Henlius Biotech, Inc.
10.26.1 Shanghai Henlius Biotech, Inc. Basic Information
10.26.2 Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.26.3 Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.26.4 Shanghai Henlius Biotech, Inc. Business Overview
10.26.5 Shanghai Henlius Biotech, Inc. Recent Developments
10.27 Suzhou Yilian Biopharmaceutical
10.27.1 Suzhou Yilian Biopharmaceutical Basic Information
10.27.2 Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.27.3 Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.27.4 Suzhou Yilian Biopharmaceutical Business Overview
10.27.5 Suzhou Yilian Biopharmaceutical Recent Developments
10.28 Beijing Hotgen Biotech
10.28.1 Beijing Hotgen Biotech Basic Information
10.28.2 Beijing Hotgen Biotech First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.28.3 Beijing Hotgen Biotech First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.28.4 Beijing Hotgen Biotech Business Overview
10.28.5 Beijing Hotgen Biotech Recent Developments
10.29 Lixin Pharmaceutical Technology
10.29.1 Lixin Pharmaceutical Technology Basic Information
10.29.2 Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.29.3 Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.29.4 Lixin Pharmaceutical Technology Business Overview
10.29.5 Lixin Pharmaceutical Technology Recent Developments
10.30 Suzhou Zejing Biopharmaceutical
10.30.1 Suzhou Zejing Biopharmaceutical Basic Information
10.30.2 Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.30.3 Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.30.4 Suzhou Zejing Biopharmaceutical Business Overview
10.30.5 Suzhou Zejing Biopharmaceutical Recent Developments
11 FIRST IN CLASS (FIC) ANTIBODY DRUG CONJUGATE (ADC) MARKET FORECAST BY REGION
11.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast
11.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Country
11.2.3 Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Region
11.2.4 South America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of First in Class (FIC) Antibody Drug Conjugate (ADC) by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of First in Class (FIC) Antibody Drug Conjugate (ADC) by Type (2026-2035)
12.1.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of First in Class (FIC) Antibody Drug Conjugate (ADC) by Type (2026-2035)
12.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Forecast by Application (2026-2035)
12.2.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT) Forecast by Application
12.2.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of First in Class (FIC) Antibody Drug Conjugate (ADC)
1.2 Key Market Segments
1.2.1 First in Class (FIC) Antibody Drug Conjugate (ADC) Segment by Type
1.2.2 First in Class (FIC) Antibody Drug Conjugate (ADC) Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 FIRST IN CLASS (FIC) ANTIBODY DRUG CONJUGATE (ADC) MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 FIRST IN CLASS (FIC) ANTIBODY DRUG CONJUGATE (ADC) MARKET COMPETITIVE LANDSCAPE
3.1 Company Assessment Quadrant
3.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Product Life Cycle
3.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Manufacturers (2020-2025)
3.4 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Manufacturers (2020-2025)
3.5 First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Average Price by Manufacturers (2020-2025)
3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
3.8 First in Class (FIC) Antibody Drug Conjugate (ADC) Market Competitive Situation and Trends
3.8.1 First in Class (FIC) Antibody Drug Conjugate (ADC) Market Concentration Rate
3.8.2 Global 5 and 10 Largest First in Class (FIC) Antibody Drug Conjugate (ADC) Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 FIRST IN CLASS (FIC) ANTIBODY DRUG CONJUGATE (ADC) INDUSTRY CHAIN ANALYSIS
4.1 First in Class (FIC) Antibody Drug Conjugate (ADC) Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF FIRST IN CLASS (FIC) ANTIBODY DRUG CONJUGATE (ADC) MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy ? April 2025
5.6.3 Global Trade Frictions and Their Impacts to First in Class (FIC) Antibody Drug Conjugate (ADC) Market
5.7 ESG Ratings of Leading Companies
6 FIRST IN CLASS (FIC) ANTIBODY DRUG CONJUGATE (ADC) MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Type (2020-2025)
6.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Type (2020-2025)
6.4 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Price by Type (2020-2025)
7 FIRST IN CLASS (FIC) ANTIBODY DRUG CONJUGATE (ADC) MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Sales by Application (2020-2025)
7.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size (M USD) by Application (2020-2025)
7.4 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Growth Rate by Application (2020-2025)
8 FIRST IN CLASS (FIC) ANTIBODY DRUG CONJUGATE (ADC) MARKET SALES BY REGION
8.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region
8.1.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region
8.1.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Region
8.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region
8.2.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region
8.2.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region
8.3 North America
8.3.1 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country
8.3.2 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country
8.4.2 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region
8.5.2 Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country
8.6.2 South America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region
8.7.2 Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 FIRST IN CLASS (FIC) ANTIBODY DRUG CONJUGATE (ADC) MARKET PRODUCTION BY REGION
9.1 Global Production of First in Class (FIC) Antibody Drug Conjugate (ADC) by Region(2020-2025)
9.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Region (2020-2025)
9.3 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Production
9.4.1 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Production Growth Rate (2020-2025)
9.4.2 North America First in Class (FIC) Antibody Drug Conjugate (ADC) Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Production
9.5.1 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Production Growth Rate (2020-2025)
9.5.2 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan First in Class (FIC) Antibody Drug Conjugate (ADC) Production (2020-2025)
9.6.1 Japan First in Class (FIC) Antibody Drug Conjugate (ADC) Production Growth Rate (2020-2025)
9.6.2 Japan First in Class (FIC) Antibody Drug Conjugate (ADC) Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China First in Class (FIC) Antibody Drug Conjugate (ADC) Production (2020-2025)
9.7.1 China First in Class (FIC) Antibody Drug Conjugate (ADC) Production Growth Rate (2020-2025)
9.7.2 China First in Class (FIC) Antibody Drug Conjugate (ADC) Production, Revenue, Price and Gross Margin (2020-2025)
10 KEY COMPANIES PROFILE
10.1 Pfizer
10.1.1 Pfizer Basic Information
10.1.2 Pfizer First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.1.3 Pfizer First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.1.4 Pfizer Business Overview
10.1.5 Pfizer SWOT Analysis
10.1.6 Pfizer Recent Developments
10.2 Johnson and Johnson
10.2.1 Johnson and Johnson Basic Information
10.2.2 Johnson and Johnson First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.2.3 Johnson and Johnson First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.2.4 Johnson and Johnson Business Overview
10.2.5 Johnson and Johnson SWOT Analysis
10.2.6 Johnson and Johnson Recent Developments
10.3 AstraZeneca
10.3.1 AstraZeneca Basic Information
10.3.2 AstraZeneca First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.3.3 AstraZeneca First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.3.4 AstraZeneca Business Overview
10.3.5 AstraZeneca SWOT Analysis
10.3.6 AstraZeneca Recent Developments
10.4 Arvinas
10.4.1 Arvinas Basic Information
10.4.2 Arvinas First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.4.3 Arvinas First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.4.4 Arvinas Business Overview
10.4.5 Arvinas Recent Developments
10.5 GSK
10.5.1 GSK Basic Information
10.5.2 GSK First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.5.3 GSK First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.5.4 GSK Business Overview
10.5.5 GSK Recent Developments
10.6 Bayer Corporation
10.6.1 Bayer Corporation Basic Information
10.6.2 Bayer Corporation First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.6.3 Bayer Corporation First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.6.4 Bayer Corporation Business Overview
10.6.5 Bayer Corporation Recent Developments
10.7 Pumis Biotechnology (BioNTech)
10.7.1 Pumis Biotechnology (BioNTech) Basic Information
10.7.2 Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.7.3 Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.7.4 Pumis Biotechnology (BioNTech) Business Overview
10.7.5 Pumis Biotechnology (BioNTech) Recent Developments
10.8 Telix
10.8.1 Telix Basic Information
10.8.2 Telix First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.8.3 Telix First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.8.4 Telix Business Overview
10.8.5 Telix Recent Developments
10.9 Merus
10.9.1 Merus Basic Information
10.9.2 Merus First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.9.3 Merus First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.9.4 Merus Business Overview
10.9.5 Merus Recent Developments
10.10 Bicara Therapeutics
10.10.1 Bicara Therapeutics Basic Information
10.10.2 Bicara Therapeutics First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.10.3 Bicara Therapeutics First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.10.4 Bicara Therapeutics Business Overview
10.10.5 Bicara Therapeutics Recent Developments
10.11 Immatics
10.11.1 Immatics Basic Information
10.11.2 Immatics First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.11.3 Immatics First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.11.4 Immatics Business Overview
10.11.5 Immatics Recent Developments
10.12 Fabhalta
10.12.1 Fabhalta Basic Information
10.12.2 Fabhalta First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.12.3 Fabhalta First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.12.4 Fabhalta Business Overview
10.12.5 Fabhalta Recent Developments
10.13 Lytgobi
10.13.1 Lytgobi Basic Information
10.13.2 Lytgobi First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.13.3 Lytgobi First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.13.4 Lytgobi Business Overview
10.13.5 Lytgobi Recent Developments
10.14 Talvey
10.14.1 Talvey Basic Information
10.14.2 Talvey First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.14.3 Talvey First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.14.4 Talvey Business Overview
10.14.5 Talvey Recent Developments
10.15 Regeneron Pharmaceuticals
10.15.1 Regeneron Pharmaceuticals Basic Information
10.15.2 Regeneron Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.15.3 Regeneron Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.15.4 Regeneron Pharmaceuticals Business Overview
10.15.5 Regeneron Pharmaceuticals Recent Developments
10.16 Ogsiveo
10.16.1 Ogsiveo Basic Information
10.16.2 Ogsiveo First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.16.3 Ogsiveo First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.16.4 Ogsiveo Business Overview
10.16.5 Ogsiveo Recent Developments
10.17 Skyclary
10.17.1 Skyclary Basic Information
10.17.2 Skyclary First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.17.3 Skyclary First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.17.4 Skyclary Business Overview
10.17.5 Skyclary Recent Developments
10.18 Truqap
10.18.1 Truqap Basic Information
10.18.2 Truqap First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.18.3 Truqap First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.18.4 Truqap Business Overview
10.18.5 Truqap Recent Developments
10.19 Litfulo
10.19.1 Litfulo Basic Information
10.19.2 Litfulo First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.19.3 Litfulo First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.19.4 Litfulo Business Overview
10.19.5 Litfulo Recent Developments
10.20 Vertex Pharmaceuticals
10.20.1 Vertex Pharmaceuticals Basic Information
10.20.2 Vertex Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.20.3 Vertex Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.20.4 Vertex Pharmaceuticals Business Overview
10.20.5 Vertex Pharmaceuticals Recent Developments
10.21 Jiangsu Hengrui Medicine
10.21.1 Jiangsu Hengrui Medicine Basic Information
10.21.2 Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.21.3 Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.21.4 Jiangsu Hengrui Medicine Business Overview
10.21.5 Jiangsu Hengrui Medicine Recent Developments
10.22 Akeso, Inc
10.22.1 Akeso, Inc Basic Information
10.22.2 Akeso, Inc First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.22.3 Akeso, Inc First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.22.4 Akeso, Inc Business Overview
10.22.5 Akeso, Inc Recent Developments
10.23 Dizal Pharma
10.23.1 Dizal Pharma Basic Information
10.23.2 Dizal Pharma First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.23.3 Dizal Pharma First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.23.4 Dizal Pharma Business Overview
10.23.5 Dizal Pharma Recent Developments
10.24 Shenzhen Yipusheng
10.24.1 Shenzhen Yipusheng Basic Information
10.24.2 Shenzhen Yipusheng First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.24.3 Shenzhen Yipusheng First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.24.4 Shenzhen Yipusheng Business Overview
10.24.5 Shenzhen Yipusheng Recent Developments
10.25 Foreseen Biotechnology
10.25.1 Foreseen Biotechnology Basic Information
10.25.2 Foreseen Biotechnology First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.25.3 Foreseen Biotechnology First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.25.4 Foreseen Biotechnology Business Overview
10.25.5 Foreseen Biotechnology Recent Developments
10.26 Shanghai Henlius Biotech, Inc.
10.26.1 Shanghai Henlius Biotech, Inc. Basic Information
10.26.2 Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.26.3 Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.26.4 Shanghai Henlius Biotech, Inc. Business Overview
10.26.5 Shanghai Henlius Biotech, Inc. Recent Developments
10.27 Suzhou Yilian Biopharmaceutical
10.27.1 Suzhou Yilian Biopharmaceutical Basic Information
10.27.2 Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.27.3 Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.27.4 Suzhou Yilian Biopharmaceutical Business Overview
10.27.5 Suzhou Yilian Biopharmaceutical Recent Developments
10.28 Beijing Hotgen Biotech
10.28.1 Beijing Hotgen Biotech Basic Information
10.28.2 Beijing Hotgen Biotech First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.28.3 Beijing Hotgen Biotech First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.28.4 Beijing Hotgen Biotech Business Overview
10.28.5 Beijing Hotgen Biotech Recent Developments
10.29 Lixin Pharmaceutical Technology
10.29.1 Lixin Pharmaceutical Technology Basic Information
10.29.2 Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.29.3 Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.29.4 Lixin Pharmaceutical Technology Business Overview
10.29.5 Lixin Pharmaceutical Technology Recent Developments
10.30 Suzhou Zejing Biopharmaceutical
10.30.1 Suzhou Zejing Biopharmaceutical Basic Information
10.30.2 Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
10.30.3 Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Product Market Performance
10.30.4 Suzhou Zejing Biopharmaceutical Business Overview
10.30.5 Suzhou Zejing Biopharmaceutical Recent Developments
11 FIRST IN CLASS (FIC) ANTIBODY DRUG CONJUGATE (ADC) MARKET FORECAST BY REGION
11.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast
11.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Country
11.2.3 Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Region
11.2.4 South America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of First in Class (FIC) Antibody Drug Conjugate (ADC) by Country
12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)
12.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of First in Class (FIC) Antibody Drug Conjugate (ADC) by Type (2026-2035)
12.1.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of First in Class (FIC) Antibody Drug Conjugate (ADC) by Type (2026-2035)
12.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Forecast by Application (2026-2035)
12.2.1 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT) Forecast by Application
12.2.2 Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size (M USD) Forecast by Application (2026-2035)
13 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Type (M USD)
Table 4. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Application
Table 5. First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Comparison by Region (M USD)
Table 6. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT) by Manufacturers (2020-2025)
Table 7. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Manufacturers (2020-2025)
Table 8. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in First in Class (FIC) Antibody Drug Conjugate (ADC) as of 2025)
Table 11. Global Market First in Class (FIC) Antibody Drug Conjugate (ADC) Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 12. Manufacturers? Manufacturing Sites, Areas Served
Table 13. Manufacturers? Product Type
Table 14. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. First in Class (FIC) Antibody Drug Conjugate (ADC) Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Type (K MT)
Table 27. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Type (M USD)
Table 28. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT) by Type (2020-2025)
Table 29. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Type (2020-2025)
Table 30. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size (M USD) by Type (2020-2025)
Table 31. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share by Type (2020-2025)
Table 32. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Price (USD/KG) by Type (2020-2025)
Table 33. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT) by Application
Table 34. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Application
Table 35. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Application (2020-2025) & (K MT)
Table 36. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Application (2020-2025)
Table 37. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Application (2020-2025) & (M USD)
Table 38. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share by Application (2020-2025)
Table 39. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Growth Rate by Application (2020-2025)
Table 40. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region (2020-2025) & (K MT)
Table 41. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Region (2020-2025)
Table 42. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region (2020-2025) & (M USD)
Table 43. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region (2020-2025)
Table 44. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2020-2025) & (K MT)
Table 45. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country (2020-2025) & (M USD)
Table 46. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2020-2025) & (K MT)
Table 47. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region (2020-2025) & (K MT)
Table 49. Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region (2020-2025) & (M USD)
Table 50. South America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2020-2025) & (K MT)
Table 51. South America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region (2020-2025) & (K MT)
Table 53. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region (2020-2025) & (M USD)
Table 54. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Production (K MT) by Region(2020-2025)
Table 55. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue (US$ Million) by Region (2020-2025)
Table 56. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Region (2020-2025)
Table 57. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. Japan First in Class (FIC) Antibody Drug Conjugate (ADC) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. China First in Class (FIC) Antibody Drug Conjugate (ADC) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 62. Pfizer Basic Information
Table 63. Pfizer First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 64. Pfizer First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 65. Pfizer Business Overview
Table 66. Pfizer SWOT Analysis
Table 67. Pfizer Recent Developments
Table 68. Johnson and Johnson Basic Information
Table 69. Johnson and Johnson First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 70. Johnson and Johnson First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 71. Johnson and Johnson Business Overview
Table 72. Johnson and Johnson SWOT Analysis
Table 73. Johnson and Johnson Recent Developments
Table 74. AstraZeneca Basic Information
Table 75. AstraZeneca First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 76. AstraZeneca First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 77. AstraZeneca Business Overview
Table 78. AstraZeneca SWOT Analysis
Table 79. AstraZeneca Recent Developments
Table 80. Arvinas Basic Information
Table 81. Arvinas First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 82. Arvinas First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 83. Arvinas Business Overview
Table 84. Arvinas Recent Developments
Table 85. GSK Basic Information
Table 86. GSK First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 87. GSK First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 88. GSK Business Overview
Table 89. GSK Recent Developments
Table 90. Bayer Corporation Basic Information
Table 91. Bayer Corporation First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 92. Bayer Corporation First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 93. Bayer Corporation Business Overview
Table 94. Bayer Corporation Recent Developments
Table 95. Pumis Biotechnology (BioNTech) Basic Information
Table 96. Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 97. Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 98. Pumis Biotechnology (BioNTech) Business Overview
Table 99. Pumis Biotechnology (BioNTech) Recent Developments
Table 100. Telix Basic Information
Table 101. Telix First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 102. Telix First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 103. Telix Business Overview
Table 104. Telix Recent Developments
Table 105. Merus Basic Information
Table 106. Merus First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 107. Merus First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 108. Merus Business Overview
Table 109. Merus Recent Developments
Table 110. Bicara Therapeutics Basic Information
Table 111. Bicara Therapeutics First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 112. Bicara Therapeutics First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 113. Bicara Therapeutics Business Overview
Table 114. Bicara Therapeutics Recent Developments
Table 115. Immatics Basic Information
Table 116. Immatics First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 117. Immatics First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 118. Immatics Business Overview
Table 119. Immatics Recent Developments
Table 120. Fabhalta Basic Information
Table 121. Fabhalta First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 122. Fabhalta First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 123. Fabhalta Business Overview
Table 124. Fabhalta Recent Developments
Table 125. Lytgobi Basic Information
Table 126. Lytgobi First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 127. Lytgobi First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 128. Lytgobi Business Overview
Table 129. Lytgobi Recent Developments
Table 130. Talvey Basic Information
Table 131. Talvey First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 132. Talvey First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 133. Talvey Business Overview
Table 134. Talvey Recent Developments
Table 135. Regeneron Pharmaceuticals Basic Information
Table 136. Regeneron Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 137. Regeneron Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 138. Regeneron Pharmaceuticals Business Overview
Table 139. Regeneron Pharmaceuticals Recent Developments
Table 140. Ogsiveo Basic Information
Table 141. Ogsiveo First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 142. Ogsiveo First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 143. Ogsiveo Business Overview
Table 144. Ogsiveo Recent Developments
Table 145. Skyclary Basic Information
Table 146. Skyclary First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 147. Skyclary First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 148. Skyclary Business Overview
Table 149. Skyclary Recent Developments
Table 150. Truqap Basic Information
Table 151. Truqap First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 152. Truqap First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 153. Truqap Business Overview
Table 154. Truqap Recent Developments
Table 155. Litfulo Basic Information
Table 156. Litfulo First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 157. Litfulo First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 158. Litfulo Business Overview
Table 159. Litfulo Recent Developments
Table 160. Vertex Pharmaceuticals Basic Information
Table 161. Vertex Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 162. Vertex Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 163. Vertex Pharmaceuticals Business Overview
Table 164. Vertex Pharmaceuticals Recent Developments
Table 165. Jiangsu Hengrui Medicine Basic Information
Table 166. Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 167. Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 168. Jiangsu Hengrui Medicine Business Overview
Table 169. Jiangsu Hengrui Medicine Recent Developments
Table 170. Akeso, Inc Basic Information
Table 171. Akeso, Inc First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 172. Akeso, Inc First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 173. Akeso, Inc Business Overview
Table 174. Akeso, Inc Recent Developments
Table 175. Dizal Pharma Basic Information
Table 176. Dizal Pharma First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 177. Dizal Pharma First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 178. Dizal Pharma Business Overview
Table 179. Dizal Pharma Recent Developments
Table 180. Shenzhen Yipusheng Basic Information
Table 181. Shenzhen Yipusheng First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 182. Shenzhen Yipusheng First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 183. Shenzhen Yipusheng Business Overview
Table 184. Shenzhen Yipusheng Recent Developments
Table 185. Foreseen Biotechnology Basic Information
Table 186. Foreseen Biotechnology First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 187. Foreseen Biotechnology First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 188. Foreseen Biotechnology Business Overview
Table 189. Foreseen Biotechnology Recent Developments
Table 190. Shanghai Henlius Biotech, Inc. Basic Information
Table 191. Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 192. Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 193. Shanghai Henlius Biotech, Inc. Business Overview
Table 194. Shanghai Henlius Biotech, Inc. Recent Developments
Table 195. Suzhou Yilian Biopharmaceutical Basic Information
Table 196. Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 197. Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 198. Suzhou Yilian Biopharmaceutical Business Overview
Table 199. Suzhou Yilian Biopharmaceutical Recent Developments
Table 200. Beijing Hotgen Biotech Basic Information
Table 201. Beijing Hotgen Biotech First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 202. Beijing Hotgen Biotech First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 203. Beijing Hotgen Biotech Business Overview
Table 204. Beijing Hotgen Biotech Recent Developments
Table 205. Lixin Pharmaceutical Technology Basic Information
Table 206. Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 207. Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 208. Lixin Pharmaceutical Technology Business Overview
Table 209. Lixin Pharmaceutical Technology Recent Developments
Table 210. Suzhou Zejing Biopharmaceutical Basic Information
Table 211. Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 212. Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 213. Suzhou Zejing Biopharmaceutical Business Overview
Table 214. Suzhou Zejing Biopharmaceutical Recent Developments
Table 215. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Region (2026-2035) & (K MT)
Table 216. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Region (2026-2035) & (M USD)
Table 217. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Country (2026-2035) & (K MT)
Table 218. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Country (2026-2035) & (M USD)
Table 219. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Country (2026-2035) & (K MT)
Table 220. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Country (2026-2035) & (M USD)
Table 221. Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Region (2026-2035) & (K MT)
Table 222. Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Region (2026-2035) & (M USD)
Table 223. South America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Country (2026-2035) & (K MT)
Table 224. South America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Country (2026-2035) & (M USD)
Table 225. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Country (2026-2035) & (Units)
Table 226. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Country (2026-2035) & (M USD)
Table 227. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Type (2026-2035) & (K MT)
Table 228. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Type (2026-2035) & (M USD)
Table 229. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Price Forecast by Type (2026-2035) & (USD/KG)
Table 230. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT) Forecast by Application (2026-2035)
Table 231. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Application (2026-2035) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Type (M USD)
Table 4. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Application
Table 5. First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Comparison by Region (M USD)
Table 6. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT) by Manufacturers (2020-2025)
Table 7. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Manufacturers (2020-2025)
Table 8. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue (M USD) by Manufacturers (2020-2025)
Table 9. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Share by Manufacturers (2020-2025)
Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in First in Class (FIC) Antibody Drug Conjugate (ADC) as of 2025)
Table 11. Global Market First in Class (FIC) Antibody Drug Conjugate (ADC) Average Price (USD/KG) of Key Manufacturers (2020-2025)
Table 12. Manufacturers? Manufacturing Sites, Areas Served
Table 13. Manufacturers? Product Type
Table 14. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. First in Class (FIC) Antibody Drug Conjugate (ADC) Market Challenges
Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
Table 26. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Type (K MT)
Table 27. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Type (M USD)
Table 28. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT) by Type (2020-2025)
Table 29. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Type (2020-2025)
Table 30. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size (M USD) by Type (2020-2025)
Table 31. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share by Type (2020-2025)
Table 32. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Price (USD/KG) by Type (2020-2025)
Table 33. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT) by Application
Table 34. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Application
Table 35. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Application (2020-2025) & (K MT)
Table 36. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Application (2020-2025)
Table 37. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Application (2020-2025) & (M USD)
Table 38. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share by Application (2020-2025)
Table 39. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Growth Rate by Application (2020-2025)
Table 40. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region (2020-2025) & (K MT)
Table 41. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Region (2020-2025)
Table 42. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region (2020-2025) & (M USD)
Table 43. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region (2020-2025)
Table 44. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2020-2025) & (K MT)
Table 45. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country (2020-2025) & (M USD)
Table 46. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2020-2025) & (K MT)
Table 47. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country (2020-2025) & (M USD)
Table 48. Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region (2020-2025) & (K MT)
Table 49. Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region (2020-2025) & (M USD)
Table 50. South America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Country (2020-2025) & (K MT)
Table 51. South America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country (2020-2025) & (M USD)
Table 52. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales by Region (2020-2025) & (K MT)
Table 53. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region (2020-2025) & (M USD)
Table 54. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Production (K MT) by Region(2020-2025)
Table 55. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue (US$ Million) by Region (2020-2025)
Table 56. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Market Share by Region (2020-2025)
Table 57. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 58. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 59. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 60. Japan First in Class (FIC) Antibody Drug Conjugate (ADC) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 61. China First in Class (FIC) Antibody Drug Conjugate (ADC) Production (K MT), Revenue (US$ Million), Price (USD/KG) and Gross Margin (2020-2025)
Table 62. Pfizer Basic Information
Table 63. Pfizer First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 64. Pfizer First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 65. Pfizer Business Overview
Table 66. Pfizer SWOT Analysis
Table 67. Pfizer Recent Developments
Table 68. Johnson and Johnson Basic Information
Table 69. Johnson and Johnson First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 70. Johnson and Johnson First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 71. Johnson and Johnson Business Overview
Table 72. Johnson and Johnson SWOT Analysis
Table 73. Johnson and Johnson Recent Developments
Table 74. AstraZeneca Basic Information
Table 75. AstraZeneca First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 76. AstraZeneca First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 77. AstraZeneca Business Overview
Table 78. AstraZeneca SWOT Analysis
Table 79. AstraZeneca Recent Developments
Table 80. Arvinas Basic Information
Table 81. Arvinas First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 82. Arvinas First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 83. Arvinas Business Overview
Table 84. Arvinas Recent Developments
Table 85. GSK Basic Information
Table 86. GSK First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 87. GSK First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 88. GSK Business Overview
Table 89. GSK Recent Developments
Table 90. Bayer Corporation Basic Information
Table 91. Bayer Corporation First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 92. Bayer Corporation First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 93. Bayer Corporation Business Overview
Table 94. Bayer Corporation Recent Developments
Table 95. Pumis Biotechnology (BioNTech) Basic Information
Table 96. Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 97. Pumis Biotechnology (BioNTech) First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 98. Pumis Biotechnology (BioNTech) Business Overview
Table 99. Pumis Biotechnology (BioNTech) Recent Developments
Table 100. Telix Basic Information
Table 101. Telix First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 102. Telix First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 103. Telix Business Overview
Table 104. Telix Recent Developments
Table 105. Merus Basic Information
Table 106. Merus First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 107. Merus First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 108. Merus Business Overview
Table 109. Merus Recent Developments
Table 110. Bicara Therapeutics Basic Information
Table 111. Bicara Therapeutics First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 112. Bicara Therapeutics First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 113. Bicara Therapeutics Business Overview
Table 114. Bicara Therapeutics Recent Developments
Table 115. Immatics Basic Information
Table 116. Immatics First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 117. Immatics First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 118. Immatics Business Overview
Table 119. Immatics Recent Developments
Table 120. Fabhalta Basic Information
Table 121. Fabhalta First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 122. Fabhalta First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 123. Fabhalta Business Overview
Table 124. Fabhalta Recent Developments
Table 125. Lytgobi Basic Information
Table 126. Lytgobi First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 127. Lytgobi First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 128. Lytgobi Business Overview
Table 129. Lytgobi Recent Developments
Table 130. Talvey Basic Information
Table 131. Talvey First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 132. Talvey First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 133. Talvey Business Overview
Table 134. Talvey Recent Developments
Table 135. Regeneron Pharmaceuticals Basic Information
Table 136. Regeneron Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 137. Regeneron Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 138. Regeneron Pharmaceuticals Business Overview
Table 139. Regeneron Pharmaceuticals Recent Developments
Table 140. Ogsiveo Basic Information
Table 141. Ogsiveo First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 142. Ogsiveo First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 143. Ogsiveo Business Overview
Table 144. Ogsiveo Recent Developments
Table 145. Skyclary Basic Information
Table 146. Skyclary First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 147. Skyclary First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 148. Skyclary Business Overview
Table 149. Skyclary Recent Developments
Table 150. Truqap Basic Information
Table 151. Truqap First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 152. Truqap First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 153. Truqap Business Overview
Table 154. Truqap Recent Developments
Table 155. Litfulo Basic Information
Table 156. Litfulo First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 157. Litfulo First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 158. Litfulo Business Overview
Table 159. Litfulo Recent Developments
Table 160. Vertex Pharmaceuticals Basic Information
Table 161. Vertex Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 162. Vertex Pharmaceuticals First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 163. Vertex Pharmaceuticals Business Overview
Table 164. Vertex Pharmaceuticals Recent Developments
Table 165. Jiangsu Hengrui Medicine Basic Information
Table 166. Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 167. Jiangsu Hengrui Medicine First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 168. Jiangsu Hengrui Medicine Business Overview
Table 169. Jiangsu Hengrui Medicine Recent Developments
Table 170. Akeso, Inc Basic Information
Table 171. Akeso, Inc First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 172. Akeso, Inc First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 173. Akeso, Inc Business Overview
Table 174. Akeso, Inc Recent Developments
Table 175. Dizal Pharma Basic Information
Table 176. Dizal Pharma First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 177. Dizal Pharma First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 178. Dizal Pharma Business Overview
Table 179. Dizal Pharma Recent Developments
Table 180. Shenzhen Yipusheng Basic Information
Table 181. Shenzhen Yipusheng First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 182. Shenzhen Yipusheng First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 183. Shenzhen Yipusheng Business Overview
Table 184. Shenzhen Yipusheng Recent Developments
Table 185. Foreseen Biotechnology Basic Information
Table 186. Foreseen Biotechnology First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 187. Foreseen Biotechnology First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 188. Foreseen Biotechnology Business Overview
Table 189. Foreseen Biotechnology Recent Developments
Table 190. Shanghai Henlius Biotech, Inc. Basic Information
Table 191. Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 192. Shanghai Henlius Biotech, Inc. First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 193. Shanghai Henlius Biotech, Inc. Business Overview
Table 194. Shanghai Henlius Biotech, Inc. Recent Developments
Table 195. Suzhou Yilian Biopharmaceutical Basic Information
Table 196. Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 197. Suzhou Yilian Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 198. Suzhou Yilian Biopharmaceutical Business Overview
Table 199. Suzhou Yilian Biopharmaceutical Recent Developments
Table 200. Beijing Hotgen Biotech Basic Information
Table 201. Beijing Hotgen Biotech First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 202. Beijing Hotgen Biotech First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 203. Beijing Hotgen Biotech Business Overview
Table 204. Beijing Hotgen Biotech Recent Developments
Table 205. Lixin Pharmaceutical Technology Basic Information
Table 206. Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 207. Lixin Pharmaceutical Technology First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 208. Lixin Pharmaceutical Technology Business Overview
Table 209. Lixin Pharmaceutical Technology Recent Developments
Table 210. Suzhou Zejing Biopharmaceutical Basic Information
Table 211. Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Product Overview
Table 212. Suzhou Zejing Biopharmaceutical First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
Table 213. Suzhou Zejing Biopharmaceutical Business Overview
Table 214. Suzhou Zejing Biopharmaceutical Recent Developments
Table 215. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Region (2026-2035) & (K MT)
Table 216. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Region (2026-2035) & (M USD)
Table 217. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Country (2026-2035) & (K MT)
Table 218. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Country (2026-2035) & (M USD)
Table 219. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Country (2026-2035) & (K MT)
Table 220. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Country (2026-2035) & (M USD)
Table 221. Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Region (2026-2035) & (K MT)
Table 222. Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Region (2026-2035) & (M USD)
Table 223. South America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Country (2026-2035) & (K MT)
Table 224. South America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Country (2026-2035) & (M USD)
Table 225. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Country (2026-2035) & (Units)
Table 226. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Country (2026-2035) & (M USD)
Table 227. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Type (2026-2035) & (K MT)
Table 228. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Type (2026-2035) & (M USD)
Table 229. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Price Forecast by Type (2026-2035) & (USD/KG)
Table 230. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT) Forecast by Application (2026-2035)
Table 231. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Application (2026-2035) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of First in Class (FIC) Antibody Drug Conjugate (ADC)
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size (M USD), 2025-2035
Figure 5. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size (M USD) (2020-2035)
Figure 6. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Product Life Cycle
Figure 13. First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Share by Manufacturers in 2025
Figure 14. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Share by Manufacturers in 2025
Figure 15. First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market First in Class (FIC) Antibody Drug Conjugate (ADC) Average Price (USD/KG) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue in 2025
Figure 18. Industry Chain Map of First in Class (FIC) Antibody Drug Conjugate (ADC)
Figure 19. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market PEST Analysis
Figure 20. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share by Type
Figure 27. Sales Market Share of First in Class (FIC) Antibody Drug Conjugate (ADC) by Type (2020-2025)
Figure 28. Sales Market Share of First in Class (FIC) Antibody Drug Conjugate (ADC) by Type in 2025
Figure 29. Market Share of First in Class (FIC) Antibody Drug Conjugate (ADC) by Type (2020-2025)
Figure 30. Market Share of First in Class (FIC) Antibody Drug Conjugate (ADC) by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share by Application
Figure 33. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Application (2020-2025)
Figure 34. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Application in 2025
Figure 35. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share by Application (2020-2025)
Figure 36. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share by Application in 2025
Figure 37. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Growth Rate by Application (2020-2025)
Figure 38. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Region (2020-2025)
Figure 39. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region (2020-2025)
Figure 40. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Country in 2024
Figure 43. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country in 2024
Figure 45. U.S. First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Country in 2024
Figure 53. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country in 2024
Figure 55. Germany First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (K MT)
Figure 66. Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Region in 2024
Figure 67. Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region in 2024
Figure 68. China First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (K MT)
Figure 79. South America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Country in 2024
Figure 80. South America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (M USD)
Figure 81. South America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country in 2024
Figure 82. Brazil First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Region in 2024
Figure 90. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region in 2024
Figure 92. Saudi Arabia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Production Market Share by Region (2020-2025)
Figure 103. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan First in Class (FIC) Antibody Drug Conjugate (ADC) Production (K MT) Growth Rate (2020-2025)
Figure 106. China First in Class (FIC) Antibody Drug Conjugate (ADC) Production (K MT) Growth Rate (2020-2025)
Figure 107. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Volume (2020-2035) & (K MT)
Figure 108. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share Forecast by Type (2026-2035)
Figure 111. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Application (2026-2035)
Figure 112. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share Forecast by Application (2026-2035)
Figure 1. Product Picture of First in Class (FIC) Antibody Drug Conjugate (ADC)
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size (M USD), 2025-2035
Figure 5. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size (M USD) (2020-2035)
Figure 6. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT) & (2020-2035)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country (M USD)
Figure 11. Company Assessment Quadrant
Figure 12. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Product Life Cycle
Figure 13. First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Share by Manufacturers in 2025
Figure 14. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue Share by Manufacturers in 2025
Figure 15. First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
Figure 16. Global Market First in Class (FIC) Antibody Drug Conjugate (ADC) Average Price (USD/KG) of Key Manufacturers in 2025
Figure 17. The Global 5 and 10 Largest Players: Market Share by First in Class (FIC) Antibody Drug Conjugate (ADC) Revenue in 2025
Figure 18. Industry Chain Map of First in Class (FIC) Antibody Drug Conjugate (ADC)
Figure 19. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market PEST Analysis
Figure 20. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Porter's Five Forces Analysis
Figure 21. Global Merchandise Trade as a Percentage Of GDP
Figure 22. US - lmports of Goods by Country
Figure 23. China Exports by Country
Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 26. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share by Type
Figure 27. Sales Market Share of First in Class (FIC) Antibody Drug Conjugate (ADC) by Type (2020-2025)
Figure 28. Sales Market Share of First in Class (FIC) Antibody Drug Conjugate (ADC) by Type in 2025
Figure 29. Market Share of First in Class (FIC) Antibody Drug Conjugate (ADC) by Type (2020-2025)
Figure 30. Market Share of First in Class (FIC) Antibody Drug Conjugate (ADC) by Type in 2025
Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 32. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share by Application
Figure 33. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Application (2020-2025)
Figure 34. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Application in 2025
Figure 35. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share by Application (2020-2025)
Figure 36. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share by Application in 2025
Figure 37. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Growth Rate by Application (2020-2025)
Figure 38. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Region (2020-2025)
Figure 39. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region (2020-2025)
Figure 40. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 41. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 42. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Country in 2024
Figure 43. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country in 2024
Figure 45. U.S. First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 46. U.S. First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Canada First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (K MT) and Growth Rate (2020-2025)
Figure 48. Canada First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size (M USD) and Growth Rate (2020-2025)
Figure 49. Mexico First in Class (FIC) Antibody Drug Conjugate (ADC) Sales (Units) and Growth Rate (2020-2025)
Figure 50. Mexico First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size (Units) and Growth Rate (2020-2025)
Figure 51. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 52. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Country in 2024
Figure 53. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 54. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country in 2024
Figure 55. Germany First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 56. Germany First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. France First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 58. France First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. U.K. First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 60. U.K. First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 61. Italy First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 62. Italy First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 63. Spain First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 64. Spain First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 65. Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (K MT)
Figure 66. Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Region in 2024
Figure 67. Asia Pacific First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region in 2024
Figure 68. China First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 69. China First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 70. Japan First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 71. Japan First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 72. South Korea First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 73. South Korea First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 74. India First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 75. India First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 76. Southeast Asia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 77. Southeast Asia First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 78. South America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (K MT)
Figure 79. South America First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Country in 2024
Figure 80. South America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (M USD)
Figure 81. South America First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Country in 2024
Figure 82. Brazil First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 83. Brazil First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 84. Argentina First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 85. Argentina First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 86. Columbia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 87. Columbia First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 88. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (K MT)
Figure 89. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share by Region in 2024
Figure 90. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (M USD)
Figure 91. Middle East and Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size by Region in 2024
Figure 92. Saudi Arabia First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 93. Saudi Arabia First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 94. UAE First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 95. UAE First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 96. Egypt First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 97. Egypt First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 98. Nigeria First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 99. Nigeria First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 100. South Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Sales and Growth Rate (2020-2025) & (K MT)
Figure 101. South Africa First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size and Growth Rate (2020-2025) & (M USD)
Figure 102. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Production Market Share by Region (2020-2025)
Figure 103. North America First in Class (FIC) Antibody Drug Conjugate (ADC) Production (K MT) Growth Rate (2020-2025)
Figure 104. Europe First in Class (FIC) Antibody Drug Conjugate (ADC) Production (K MT) Growth Rate (2020-2025)
Figure 105. Japan First in Class (FIC) Antibody Drug Conjugate (ADC) Production (K MT) Growth Rate (2020-2025)
Figure 106. China First in Class (FIC) Antibody Drug Conjugate (ADC) Production (K MT) Growth Rate (2020-2025)
Figure 107. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Volume (2020-2035) & (K MT)
Figure 108. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Size Forecast by Value (2020-2035) & (M USD)
Figure 109. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Market Share Forecast by Type (2026-2035)
Figure 110. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share Forecast by Type (2026-2035)
Figure 111. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Sales Forecast by Application (2026-2035)
Figure 112. Global First in Class (FIC) Antibody Drug Conjugate (ADC) Market Share Forecast by Application (2026-2035)
